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Abstract
Interleukin 4 (IL-4) is a critical cytokine implicated with TH2 immune reactions, which are linked to pathologic
conditions of allergic diseases. In that context, the initiation of TH2 responses can critically depend on early basophil-
derived IL-4 to activate T-cell responses, which then amplify IL-4 secretion. As a pleiotropic cytokine, IL-4 acts on a
broad variety of hematopoietic and non-hematopoietic cells. However, the effect of IL-4 on basophils themselves,
which are emerging as relevant players in allergic as well as autoimmune diseases, was only scarcely addressed so far.
Here we used in vitro-differentiated mouse basophils to investigate the direct effects of IL-4 on cellular viability and
surface expression of the high-afﬁnity receptor for IgE, FcεRI. We observed that IL-4 elicits pronounced pro-survival
signaling in basophils, delaying spontaneous apoptosis in vitro to a degree comparable to the known pro-survival
effects of IL-3. Our data indicate that IL-4-mediated survival depends on PI3K/AKT signaling and—in contrast to IL-3—
seems to be largely independent of transcriptional changes but effectuated by post-translational mechanisms
affecting BCL-2 family members among others. Additionally, we found that IL-4 signaling has a stabilizing effect on the
surface expression levels of the critical basophil activation receptor FcεRI. In summary, our ﬁndings indicate an
important regulatory role of IL-4 on in vitro-differentiated mouse basophils enhancing their survival and stabilizing
FcεRI receptor expression through PI3K-dependent signaling. A better understanding of the regulation of basophil
survival will help to deﬁne promising targets and consequently treatment strategies in basophil-driven diseases.
Introduction
The source of interleukin (IL)-4 in vivo is thought to
derive upon activation from at least three different cell
types, including mast cells, basophils as well as a sub-
population of T cells. Once released, IL-4 acts as a pro-
minent cytokine in type 2 immune reactions fulﬁlling
diverse functions. In T cells, upon activation of naive
peripheral CD4+ T cells autocrine IL-4 drives their cel-
lular growth and differentiation1. Consequently, naive
T cells mature into TH2 cells leading to the initiation of
TH2 immune reactions. In general, IL-4 represents a
pleiotropic cytokine acting on different cells. Besides its
substantial effect on the viability of T and B lymphocytes2,
IL-4 is also implicated with tissue adhesion and inﬂam-
mation leading to the recruitment of T cells and eosino-
phils (reviewed in ref. 3). Moreover, IL-4 promotes class
switching in B cells for de novo synthesis of immu-
noglobulins, in particular IgE, which together with TH2
lymphocytes execute a protective host defense against
parasite infections. However, allergen-speciﬁc TH2 reac-
tions are also associated with atopic disorders and are
recognized to take part in the pathogenic conditions of
progressive systemic sclerosis, cryptogenic ﬁbrosing
alveolitis4, and in some forms of systemic autoimmune
diseases5. Especially upon allergen crosslinking of the
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high-afﬁnity IgE receptor, FcεRI, or through IgE-
independent activation, de novo-synthesized cytokines
such as IL-4 are released from mast cells and basophils6.
Besides secreting IL-4, mast cells also directly respond to
this cytokine. IL-4 serves not only as a growth factor for
human intestinal mast cells but also enhances IgE-
dependent mediator release6 and promotes de novo
expression of other cytokines, such as IL-3, IL-5 and
IL-13, whereas the production of IL-6 is suppressed7.
Likewise, human intestinal mast cells were recognized to
prolong their survival through IL-4-induced priming. By a
reversible process, IL-4 leads to upregulation of mast cell
proliferation as well as increased FcεRI expression8,9. Yet,
IL-4 alone is not able to affect mast cell survival but
strongly enhances mast cell proliferation and TH2-type
cytokine production in presence of stem cell factor8. In
terms of survival regulation, IL-4 was reported to induce
the anti-apoptotic BCL-2 family members BCL-2 and
BCL-XL and increase survival of cultured bone marrow-
derived mouse mast cells in a STAT6-dependent man-
ner10. IL-4 was further seen to prevent cell death in
multiple hematopoietic cell types through the activation
of the PI3K/AKT pathway2. From studies with the IL-3-
dependent myeloid progenitor cell line FDCP-2, it became
clear that the effect of IL-4 is distinct from that of IL-3,
activating speciﬁc non-redundant tyrosine phosphoryla-
tions strongly associated with PI3K signaling, while IL-3
was found to trigger PI3K activation only weakly11. With
regards to the related eosinophils and neutrophils, con-
ﬂicting effects of IL-4 on human eosinophils were
reported12,13, whereas in human neutrophils, IL-4 was
found to enhance general RNA synthesis, resulting in
enhanced survival and activation of cytoskeletal
rearrangements14.
Interestingly, basophils were recognized to release a
considerable amount of IL-4 upon activation, which then
serves as a critical source of early IL-4 to initiate TH2
immune reactions through primary T-cell activation15.
Moreover, many physiological and pathological condi-
tions were revealed to be linked to speciﬁc basophil-
derived IL-4, which impacts on hematopoietic (T cells,
B cells, ILC2s, and macrophages) as well as on non-
hematopoietic cells (ﬁbroblasts and endothelial cells)
(reviewed in ref. 16). These include the protective effects
against parasites and infectious bacteria but also certain
allergic and autoimmune diseases. Moreover, several
studies indicate that IL-4 increases histamine release of
human basophils as well as mast cells17,18.
Although IL-4 potently affects multiple cell types within
the hematopoietic system, its speciﬁc effect on basophils
is poorly understood. In particular, it is not clear whether
and how IL-4 directly inﬂuences basophil survival. In
regard of the emerging role of basophils especially in TH2-
related diseases, such as diverse allergic disorders19,
mechanistic understanding of the regulation of basophil
survival may offer novel insights into basophil mediated
disease progression. To address this question, we took
advantage of an established model of in vitro-
differentiated mouse basophils, termed IL-3condHoxb8
basophils20,21, to investigate molecular mechanisms reg-
ulating mouse basophil survival.
Results
IL-4 induces dose-dependent basophil survival
and stabilizes cellular granularity and size
Throughout this study, we traced the impact of IL-4 on
survival of basophils using the IL-3condHoxb8 model of in
vitro-differentiated mouse basophils20,21. Upon complete
basophil maturation, in vitro-differentiated mouse baso-
phils spontaneously underwent apoptotic cell death, as
assessed by ﬂow cytometric analysis of cellular viability
over time (Fig. 1a). Interestingly, this effect could be sig-
niﬁcantly delayed by the administration of recombinant
IL-4, even though the impact was less potent compared to
IL-3, which is a well-known and critical pro-survival
cytokine for basophils (Fig. 1a and ref. 22). Flow cyto-
metric analysis conﬁrmed the surface expression of
CD124, the alpha subunit of the IL-4 receptor (Supple-
mentary Figure S1). IL-4 did not further enhance IL-3
mediated basophil survival, indicating that the potent
effect of IL-3 might have already reached its plateau.
To prove the speciﬁcity for IL-4-induced survival,
we administered neutralizing anti-IL-4 antibody, which
completely abolished the IL-4-mediated, but not the IL-3-
mediated, increase in survival (Fig. 1a). Furthermore, the
addition of a neutralizing anti-IL-3 antibody did not
reduce the IL-4 mediated effects, indicating that IL-4 does
not enhance survival via autocrine IL-3 (Fig. 1a). As
shown in Fig. 1b, IL-4 elicited both a dose- and time-
dependent increase in basophil survival. Moreover, and
similar to IL-3, addition of IL-4 prevented the loss of
basophil granularity and decrease in cell size that occurs
upon cytokine withdrawal, even though to lesser extents
(Fig. 1c, d). Taken together, these data demonstrate that
IL-4 triggers signiﬁcant and IL-3-independent pro-
survival signaling in in vitro-differentiated mouse
basophils.
IL-4-induced basophil survival is mediated through
PI3K-dependent and largely transcription-independent
signaling
We recently reported that IL-3 mediates pro-survival
signaling in basophils by transcriptional and post-
translational activation of pro-survival BCL-2 family
members22. Interestingly, and in contrast to IL-3, quan-
titative PCR array data showed that mRNA levels of
apoptosis regulating genes only marginally changed upon
IL-4 exposure (Fig. 2a). These results indicate that the
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pro-survival signaling of IL-4 is largely independent of
gene transcription and may thus rather be mediated
through post-transcriptional regulation. In hematopoietic
cells, IL-4-mediated survival has been linked to PI3K >
AKT signaling and was shown to result in speciﬁc and
non-redundant tyrosine phosphorylation compared to
IL-3, which triggers a weaker activation of PI3K in a
factor-dependent myeloid cell line2. To test if the pro-
tective effect of IL-4 on basophil survival is indeed regu-
lated by PI3K, we used the potent and stable PI3K
(see ﬁgure on previous page)
Fig. 1 Dose-dependent increase of basophil survival by IL-4. a Survival of in vitro-differentiated basophils in presence or absence of recombinant
cytokines (10 ng/ml IL-3, 20 ng/ml IL-4) or blocking antibody (anti-IL-4 and anti-IL-3, 10 μg/ml each; both antibodies are of the same isotype) over
time was measured by ﬂow cytometry using annexin V/PI exclusion (n ≥ 3, ±SD). Statistical analysis using multiple t test with Holm-Sidak post hoc for
multiple comparison shows p-values of indicated comparisons, non-signiﬁcant results highlighted in gray. b Quantiﬁcation of GFP-annexin V/PI
double-negative cells by ﬂow cytometry illustrating both dose and time-dependent survival of in vitro-differentiated basophils upon IL-4 stimulation
(24 h, 48 h, 72 h, and 96 h) (n ≥ 4, ±SD, two-way ANOVA with Dunnett’s multiple comparison correction, α= 0.05. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001). c Granularity and cellular size in untreated or cytokine-treated basophils was determined by side scatter (SSC) and forward scatter
(FSC), respectively (n ≥ 3, ± SD). Table shows statistical analysis of quantiﬁed SSC and FSC graphs. p-values calculated by two-way ANOVA with
Turkey’s multiple comparison correction. p < 0.05 is considered a statistically signiﬁcant difference between the treatments. d Representative
cytospins of in vitro-differentiated basophils upon 6 or 24 h of incubation without or with cytokine at indicated concentrations. Images were
acquired with a Panoramic Midi slide scanner and analyzed by CaseViewer software, both from 3DHISTECH (Budapest, Hungary), scale bars
correspond to 20 μm
Fig. 2 PI3K driven, but transcriptionally independent, regulation of IL-4-mediated basophil survival. a PCR array of apoptosis-related genes
comparing mRNA levels of in vitro-differentiated basophils upon 3 h of incubation with or without 20 ng/ml IL-4. Using the SA Biosciences software,
Ct values were normalized to the average of ﬁve different housekeeping genes (β actin, β2 microglobulin, Gapdh, Gusb, and Hsp90ab1) and
linearized with the standard formula for qPCR (2−(Ctsample−Ctcontrol)). The y-axis corresponds to the expression of IL-4-treated cells, while the x-axis
corresponds to the untreated controls. The continuous line depicts the equal expression level in both IL-4 and untreated basophils, whereas the
dotted lines display a threshold of twofold increase or decrease of the mRNA expression comparing IL-4 over untreated. b–d Viability measurements
of in vitro-differentiated basophils over time evaluated by GFP-annexin V/PI exclusion using ﬂow cytometry (n ≥ 3, ± SD, statistics shown in
Supplementary Table S2). b Using LY294002 at a concentration of 30 μM, the effect of PI3K inhibition was tested with or without cytokines (20 ng/ml
IL-4 or 10 ng/ml IL-3). c The mTOR inhibitor rapamycin was added at two different concentrations with or without IL-4 co-treatment. d Administration
of the selective PIM-1 inhibitor SMI-4a at a concentration of 20 μM alone or in combination with IL-4 or IL-3. Same data as in Fig. 1a are included in
(b–d) for untreated, IL-4 or IL-3 treatments (n ≥ 5)
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inhibitor LY294002. As shown in Fig. 2b, the pro-survival
effect of IL-4 could be completely abolished as soon as
LY294002 was co-administered, while the protective
effect of IL-3 was only partially diminished. Moreover,
spontaneous cell death in the absence of speciﬁc cytokines
was further enhanced by LY294002 implicating the rele-
vance of PI3K for cell survival already at steady state (see
also vehicle control in Supplementary Figure S2). Of note,
the effect of IL-4-induced basophil survival as well as its
dependence on PI3K could be conﬁrmed in bone marrow-
derived c-kit−CD49b+FcεRI+/IgE+ primary mouse baso-
phils (Supplementary Figure S3a, b). Even though PI3K
can activate the mTOR pathway, which is well known to
regulate cell growth, proliferation, and survival23, inhibi-
tion of mTOR by rapamycin had no signiﬁcant effect on
basophil viability suggesting that mTOR is not critical for
IL-4 mediated survival in that context (Fig. 2c).
Given that Provirus integration site for Moloney leu-
kemia virus 1 (PIM-1) was reported to be an important
kinase for human basophil survival downstream of IL-3,
Fig. 3 IL-4 triggers rapid changes in AKT-mediated protein phosphorylation pattern. a Data of a protein phospho-array directed against a
distinct set of phosphorylation sites involved in the AKT-dependent signaling cascade comparing IL-4 treated in vitro-differentiated (y-axis) to
untreated basophils (x-axis). The continuous line corresponds to equal phosphorylation status in IL-4 and untreated, whereas the dotted lines
represent the arbitrary chosen threshold of a twofold increase or decrease of IL-4-treated over untreated after 2.5 h of incubation. See complete list
and fold increase/decrease in phosphorylation in Supplementary Table S1. b Western blot of in vitro-differentiated mouse basophils after indicated
time points upon cytokine treatment with IL-4 (20 ng/ml) or IL-3 (10 ng/ml) with or without kinase inhibitors (PI3K inhibitor LY294002, 30 μM; PIM-1
inhibitor SMI-4a, 20 μM), depicted as a representative example using near-infrared ﬂuorescence (n ≥ 3). Flow cytometric analysis of in vitro-
differentiated basophils upon (c) S63845, (d) ABT-199, (e) ABT-263 or (f) WEHI-539 administration at indicated concentrations with and without
cytokines (n= 4, ±SD, see statistical analysis in Supplementary Table S3). Same data as in Fig. 1a are included in (c–f) for untreated or IL-4 treatments
(n ≥ 5)
Reinhart and Kaufmann Cell Death and Disease  (2018) 9:713 Page 5 of 12
Ofﬁcial journal of the Cell Death Differentiation Association
and that LY294002 at a concentration of 30 µM also
inhibits PIM-121,24, we tested the effect of a speciﬁc PIM-1
inhibitor, SMI-4a. As shown in Fig. 2d, treatment with
SMI-4a partially but signiﬁcantly counteracted IL-4-
mediated survival (p= 0.0083/0.0172/0.0089/0.0058 at
time points 24/48/72/96 h, multiple t test with post hoc of
Holm-Sidak correction; see entire statistics of Fig. 2b–d in
Supplementary Table S2). In summary, these data criti-
cally identify transcription-independent events down-
stream of PI3K to mediate survival of mouse basophils in
response to IL-4, while PIM-1 may also partially
contribute.
IL-4 induces post-translational modiﬁcations through
protein phosphorylation downstream of AKT
The above results point toward an important
transcription-independent contribution of the PI3K >
AKT signaling pathway downstream of IL-4 mediated
basophil survival. In support of this, phospho-AKT pro-
tein levels increased in response to IL-4 treatment (Sup-
plementary Figure S4a). A protein phosphorylation array
integrating a broad range of phosphorylation targets of
protein kinase B, PKB/AKT, was performed to compare
the phosphorylation proﬁles of untreated vs. IL-4 treated
basophils. This resulted in a list of potential candidates
that may act as important downstream targets (Fig. 3a and
see complete data list in Supplementary Table S1). Can-
didates included glycogen synthase kinase-3 (GSK-3),
which is known to be inactivated through AKT-mediated
phosphorylation, and which in its active state was shown
to inactivate the pro-survival BCL-2 family member
MCL-1 through phosphorylation at S159 upon IL-3
deprivation25,26. Therefore, the identiﬁed increase in
GSK-3 phosphorylation upon IL-4 suggests its inhibition
and subsequent stabilization of MCL-1 to enhance the
survival of in vitro-differentiated basophils, which was
indeed supported by a slight increase in MCL-1 protein
levels after IL-4 addition compared to untreated controls
(Fig. 3b and see quantiﬁcation in Supplementary Fig-
ure S4b). Moreover, co-administering PIM-1 or PI3K
inhibitor reversed IL-4 or IL-3 induced increase in MCL-1
(Fig. 3b). Nevertheless, using the novel and highly speciﬁc
MCL-1 inhibitor S63845 at a concentration of 1 μM27, we
could see only a minimal decrease in basophil viability.
Only at a very high concentration of 10 μM S63845 was
the pro-survival effect of IL-4 completely abolished
(Fig. 3c).
Likewise, our results implicate a post-translational
activation of BCL-2 by IL-4 (Fig. 3a), as the activating
phosphorylation of BCL-2 at Thr-69 enhances its pro-
survival function28,29. Supporting the importance of IL-4
mediated basophil survival, speciﬁc inhibition of BCL-2 by
the BH3 mimetic ABT-199 totally overcame IL-4-induced
survival already at concentrations as low as 0.1 μM
(Fig. 3d). The simultaneous inhibition of BCL-2 and BCL-
XL by ABT-263 resulted in an even more potent cell death
induction (Fig. 3e). Interestingly, and similar to IL-3
mediated mouse basophil survival, the inhibition of BCL-
XL alone by WEHI-539 was already sufﬁcient to partially
counteract the pro-survival effect of IL-4 (Fig. 3f) (see
statistical analyses of Fig. 3c–f in Supplementary
Table S3). Additionally, IL-4 exposure led to a reportedly
inactivating hyperphosphorylation of the pro-apoptotic
BH3 only proteins BAD and BIM (Fig. 3a)30,31. Along the
same line, we found a potent increase in phosphorylation
of 14-3-3 by IL-4, which was shown to result in its
stronger binding and blocking of the pro-apoptotic
functions of BIM and BAD32,33, which would support
the enhanced survival of basophils upon IL-4 exposure.
Besides, we also observed an increase in phosphoryla-
tion of spleen tyrosine kinase SYK and de-
phosphorylation of LYN (Fig. 3a), both of which are
activating modiﬁcations34,35. LYN and SYK are in this
respect interesting because they are known to function
upstream of AKT and downstream of FcεRI, one of the
most important activation receptors of basophils. How-
ever, it remains unclear if and how IL-4 receptor signaling
crosstalks to FcεRI in basophils.
IL-4 stabilizes the surface expression levels of FcεRI
through a PI3K-dependent mechanism
In human mast cells, IL-4 was shown to increase the
surface expression of FcεRI36,37. Because LYN and SYK,
both proximal kinases downstream of FcεRI, were identi-
ﬁed in the protein phospho-array to be activated upon IL-4
stimulation (Fig. 3a), we hypothesized that IL-4 receptor
signaling might also be linked to FcεRI expression in
basophils. Therefore, we investigated the surface expres-
sion levels of FcεRI on in vitro-differentiated basophils
upon IL-4 exposure over time. Already 24 h after cytokine
exposure, we found increased FcεRI surface expression
compared to its initial level (Fig. 4a), while the unrelated
surface protein CD45 did not show such changes (Fig. 4b).
As shown in Fig. 4c (see statistical analysis in Supple-
mentary Table S4), surface FcεRI was signiﬁcantly stabi-
lized over time by IL-4 compared to control, yet, to lower
extents compared with IL-3. Interestingly, however, we
observed that the increase of FcεRI surface expression
after IL-3 administration was further, and signiﬁcantly,
increased as well as prolonged upon co-administration of
IL-4 (Fig. 4c). These data indicate that IL-4 contributes to
an increase of surface FcεRI levels in basophils. Of note,
similar prolongation of increased FcεRI expression could
be obtained by the re-administration of IL-3 after 33 h of
incubation (Supplementary Figure S5a). We further found
a strong negative correlation between the expression levels
of FcεRI and the CD123 unit of the IL-3 receptor, even
though this may likely be caused by increased endocytic
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uptake of IL-3/CD123 complex as a form of negative
feedback regulation (Supplementary Figure S5b, c). The
cytokine-induced increase of surface FcεRI was totally
abolished by the co-administration of the PI3K inhibitor
LY294002 (Fig. 4d) for both, single or combined treat-
ments with IL-4 and IL-3, respectively. These data indicate
that both IL-4 and IL-3 positively regulate surface
expression levels of FcεRI through PI3K signaling-
dependent mechanisms. The stabilization of surface
FcεRI expression by IL-4, and the role of PI3K therein,
were conﬁrmed in c-kit-CD49b+FcεRI+/IgE+ bone
marrow-derived primary mouse basophils (Supplementary
Figure S3c).
Discussion
Mast cells, which share many features with basophils,
are potently inﬂuenced by IL-4. Speciﬁcally, IL-4 was
shown to serve as a growth factor and to enhance
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Fig. 4 IL-4 stabilizes the surface expression level of FcεRI on in vitro-differentiated basophils in a PI3K-dependent manner. Flow cytometric
analysis of FcεRI (a, c, d) and CD45 (b) surface expression levels, gated on viable cells and depicted as (a, b) representative histograms at 24 h of
incubation and (c, d) of mean ﬂuorescence intensity (MFI) relative to the 0 h time point, over time (n ≥ 3, ±SD, see statistical analysis of (c, d) in
Supplementary Table S4). c Comparison of FcεRI expressions upon single or combinational cytokine administration at indicated concentrations
compared to untreated over 48 h. d Combinational treatment with 30 μM of the PI3K inhibitor LY294002 with either IL-4 and/or IL-3. Same data from
(c) are included
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IgE-dependent degranulation of human intestinal mast
cells6, to promote cytokine expression3 and to enhance
human mast cell survival38. Here we could show that IL-4
likewise enhances viability of in vitro-differentiated mouse
basophils in a dose- and time-dependent manner. Even
though CD124 was strongly expressed on basophils and
IL-4 enhanced basophil viability independently of IL-3, we
cannot exclude the possibility that autocrine signaling of
yet unknown factors downstream of IL-4 also contribute
to the pro-survival effect. Although IL-3 constitutes the
most potent survival factor for basophils, IL-4 could
partially compensate for the absence of IL-3. Of note,
Bailey et al.39 showed that the viability of mouse bone
marrow-derived mast cells is negatively affected by long-
term (>10 days) presence of IL-4 in the culture medium.
But due to their much shorter lifespan, long-term
effects of IL-4 on basophil viability could not be
investigated here.
Although IL-4 is well known to induce transcription
through the transcription factors JAK/STAT640, we did
not observe transcriptional changes of key apoptosis reg-
ulating genes at short time points after IL-4 stimulation.
This suggests an important contribution of post-
translational regulation of basophil survival by IL-4. We
accordingly identiﬁed the PI3K pathway to play a major
role in IL-4 mediated survival of basophils, whereas PIM-1
was found to partially contribute as well. The data from
the AKT phospho-array strongly indicate the involvement
of AKT downstream of PI3K; however further investiga-
tions are needed to assess if PI3K-dependent but AKT-
independent pathways also contribute. As reported by
others, growth factors and cytokines can enhance PIM-1
protein levels through transcriptional regulation that
might operate in synergy with AKT to overcome pro-
apoptotic signaling41. Even though former studies sug-
gested the importance of PIM-1 in IL-3-mediated human
basophil survival, using a speciﬁc PIM-1 inhibitor, we
could not conﬁrm this effect in in vitro-differentiated
mouse basophils. Those results point toward possible
differences in the regulation of basophil survival between
humans and mice that need to be further investigated.
Although we saw a prominent activation of mTOR and
its downstream substrate p70S6K in the phospho-array
(Fig. 3a), inhibition of mTOR by rapamycin did not affect
basophil viability. Those results indicate the dispensability
or redundancy of mTOR signaling in the anti-apoptotic
signaling of IL-4 in our cellular system. On the other
hand, we observed an inactivating phosphorylation of
GSK-3 in response to IL-4, which has been described to
be mediated by AKT. Even though we did not detect a
signiﬁcant change in protein level (Fig. 3b), subsequent
loss of GSK-3 activity may directly impact on protein
stabilization, such as of the pro-survival protein MCL-1.
This was supported by the increase in MCL-1 protein
levels upon IL-4 administration, even though the effect
was not as clear as seen with IL-3. We recently reported
that MCL-1 is not the most critical pro-survival BCL-2
family member to mediate IL-3-driven survival of mouse
basophils22. We obtained similar results in the context of
IL-4 using the speciﬁc MCL-1 inhibitor S63845. In con-
trast, we previously identiﬁed MCL-1 as a critical pro-
survival protein in human basophils22, again underlining
important differences between mouse and human
basophils.
Previous studies showed that phosphorylation of BCL-2
importantly regulates fate decision of IL-3 mediated sur-
vival and even suggested the necessity of BCL-2 phosphor-
ylation for its full and potent survival phenotype22,28,29,42.
Likewise, we found increased phosphorylation of BCL-2
in IL-4 mediated survival indicating the impact of the
enhanced pro-survival function of BCL-2 in IL-4-induced
basophil viability. This is supported by our data on BCL-
2-, or BCL-2- and BCL-XL-selective BH3 mimetics (ABT-
199 and ABT-263), respectively, both of which completely
abrogated IL-4-mediated survival at low concentrations.
However, by comparing the BCL-XL speciﬁc inhibitor
WEHI-539 to ABT-199, it became clear that BCL-2 might
be of higher importance for IL-4-mediated basophil sur-
vival. On the other hand, we also found changes in AKT-
mediated phosphorylation of pro-apoptotic proteins
downstream of IL-4. As previously shown, survival factors
such as IL-3 block the apoptotic activity of BAD through
phosphorylation of speciﬁc serine residues43–45. Interest-
ingly, it was shown that the BAD phosphorylation at Ser-
155 requires the preceding phosphorylation at Ser-136
mediated by PI3K/AKT45. This leads to the recruitment of
14-3-3 proteins to increase the accessibility of Ser-155 to
other survival-promoting kinases44. These ﬁndings sup-
port our results of increased BAD and 14-3-3 phosphor-
ylations and suggest that these proteins may further
contribute to IL-4-mediated basophil survival.
Of interest is the ﬁnding that IL-4 signaling crosstalks to
the regulation of FcεRI surface expression in mouse
basophils. Our data support the work by others, showing
that IL-4 leads to the upregulation of FcεRI expression in
human mast cells8,9,36,37. This effect might be of rele-
vance, as FcεRI, upon antigen crosslinking, is among the
most important activating receptors on basophils. Addi-
tionally, IL-4-mediated increase of surface FcεRI would
further conﬁrm the ﬁnding that IL-4 increases the reac-
tivity of human basophils17. Nevertheless, whether the
increase in FcεRI on mouse basophils provokes enhanced
mediator release upon activation similar to mast cells still
needs to be clariﬁed. Interestingly, and in contrast to the
effect on basophil viability, the combinational treatment
of in vitro-differentiated basophils with IL-4 and IL-3
showed an additive effect on increase of surface FcεRI
expression. This indicates that the regulation of FcεRI
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surface expression is regulated through different path-
ways. Particularly in basophils, SYK as well as LYN are of
high importance in the initiation of FcεRI signaling,
leading to histamine release and degranulation of baso-
phils and mast cells46. The clustering of FcεRI on the
surface of basophils (as well as mast cells) triggers a cas-
cade of downstream signals including the activation of the
Src family protein tyrosine kinase LYN and subsequent
recruitment of SYK tyrosine kinase. Based on our ﬁnd-
ings, including the activation of LYN and SYK down-
stream of IL-4, the process of IL-4-induced basophil
survival may be linked to the surface receptor regulation
of FcεRI, and its downstream signaling.
Sharing the IL-4Rα chain with IL-4, IL-13 might like-
wise enhance basophil viability. However, as shown in
Supplementary Figure S6a, IL-13 alone was not sufﬁcient
to critically prolong the lifespan of basophils. Yet, a slight
increase was still measurable. This suggests, that during
inﬂammatory responses, the mixture of distinct cytokines
might contribute to enhancement of cell survival. Even
the alarmin cytokine IL-33, which is known to play a
pivotal role in allergic inﬂammation and directly affects
human basophil function47, was found to partially aug-
ment basophil survival rate at earlier time points (24 and
48 h), but did not improve viability upon simultaneous
stimulation with IL-3 (Supplementary Figure S6b). This
indicates that—besides IL-3—basophil viability is inﬂu-
enced by various pro-inﬂammatory cytokines, which
potentially impact basophil lifespan during inﬂammatory
reactions.
In summary, we revealed the potential of IL-4 to
enhance the viability of mouse basophils, which is criti-
cally mediated through PI3K > AKT signaling and
involves important post-translational mechanisms (sum-
marized in Fig. 5). However, not only the signiﬁcant
impact of IL-4 on basophil survival but also its positive
effect on the surface expression level of FcεRI implicates
the crucial importance of IL-4-mediated signaling on
basophils and its speciﬁc action during immune responses
(Fig. 5). In particular, during TH2 responses, which are
associated with a potent release of IL-4 and consequently
contribute to diverse diseases such as allergic and auto-
inﬂammatory disorders, improved understanding of the
regulation of basophil survival will help to better under-
stand basophil-related pathogenesis and may offer novel
treatment strategies.
Materials and methods
Mice and reagents
C57BL/6J mice were maintained under pathogen-free
conditions in individually ventilated cages (IVC). Ani-
mal experiments were approved by the animal experi-
mentation review board of the canton of Bern (BE12/14,
BE138/16).
RPMI-1640 AQmedia™, propidium iodide (PI), 4-
hydroxytamoxifen (4-OHT), and SMI-4a were purchased
from Sigma-Aldrich Chemie GmbH (Buchs, CH). Fetal calf
serum (FCS, Sera Pro, ultra-low endotoxin) was purchased
from Pan Biotech (Aidenbach, DE), penicillin–streptomycin
from Gibco (Thermo Fisher Scientiﬁc, Waltham, MA, US).
As a source of mouse IL-3, WEHI-3B cell-conditioned
medium was used and produced as previously descri-
bed21,48. Recombinant mouse IL-4, IL-3, IL-33, and IL-13
were purchased from Peprotech (London, UK). Q-VD-OPh
was purchased from SM Biochemicals (Anaheim, CA, US).
ABT-199 (Venetoclax/Venclexta) was manufactured by
BioVision (Milpitas, CA, US), ABT-263 (Navitoclax) by
Selleck Chemicals (Houston, TX, US), WEHI-539 hydro-
chloride was purchased from Hycultec (Beutelsbach, DE),
S63845 from ApexBio (Houston, TX, US). Recombinant
His6-tagged GFP-Annexin V was puriﬁed as previously
AKT
BIM/
BAD
BCL-2
GSK-3
Mouse Basophil Survival
IL-4/IL-4R
LYN
SYK
?
FcεRI
?
PIM-1PI3K
BCL-XL
Fig. 5 IL-4-mediated survival and surface FcεRI stabilization.
Cartoon depicting a model of how IL-4 may lead to increased mouse
basophil survival through the kinase activation of PI3K > AKT and
PIM-1, which results in stabilization of pro-survival proteins like BCL-2
and destabilization of pro-apoptotic proteins such as BIM and BAD.
Moreover, beside the stabilization of FcεRI surface expression through
IL-4 signaling, IL-4 was also seen to affect SYK and LYN. However, the
exact mechanism of SYK and LYN activation as well as the link
between IL-4 signaling and FcεRI expression is not clear
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described49,50. LY-294002 and rapamycin were from Enzo
Life Science (Lausen, CH).
In vitro differentiation of mouse basophils
Conditional Hoxb8-immortalized basophil committed
myeloid progenitors, termed IL-3condHoxb8, were gener-
ated from bone marrow of WT mice and differentiated
in vitro into mature basophils as previously described20,21,
and are referred to as in vitro-differentiated mouse
basophils throughout this manuscript. Cells were cultured
in RPMI-1640 AQmedia supplemented with 10% FCS,
100 U/ml penicillin, 100 µg/ml streptomycin, 10% WEHI-
3B cell-conditioned medium as a source of mouse IL-3
(ca 200 pg/ml ﬁnal concentration) and 0.1 μM 4-OHT.
Upon removal of 4-OHT, mature basophils were obtained
within 6 days. To conﬁrm basophil differentiation, cells
were stained for the surface marker proﬁle CD-117/
c-kit-FcεRI+, using the following antibodies (all from
BioLegend, San Diego CA, US): hamster anti-FcεRI (clone
MAR-1) and rat anti-CD117 (c-kit, clone 2B8) and mea-
sured by ﬂow cytometry (FACS Verse or FACS Lyric, BD
BioScience)20,21. Data were analyzed by FlowJo V.10.1.
Cell death measurement by ﬂow cytometric analysis
In vitro-differentiated basophils were thoroughly washed
with PBS prior to incubation with the indicated stimuli, in
the presence or absence of high concentrations of
recombinant mouse IL-3 (10 ng/ml) or recombinant
mouse IL-4 (20 ng/ml) with or without rat anti-IL-4 (clone
11B11, BioLegend) or rat anti-IL3 (clone MP2-8F8, Bio-
Legend) neutralizing antibodies. Basophils were stained
with GFP-annexin V diluted in FACS buffer (150mM
NaCl, 4 mM KCl, 2.5 mM CaCl2, 1 mM MgSO4, 15mM
HEPES pH 7.2, 2 % FCS and 10mM NaN3) for 20min on
ice in the dark. Following one washing step with FACS
buffer, cells were resuspended in FACS buffer containing
2 μg/ml of PI and subsequently measured by ﬂow cyto-
metry (FACS Verse or FACS Lyric, BD Biosciences,
San Jose, CA, US). Data were analyzed using FlowJo ver-
sion 10.1., where (excluding debris and doublets) GFP-
annexin V and PI double-negative cells were considered
viable and displayed as percentage of overall survival at
indicated time points.
Flow cytometric analysis of surface receptor expressions
After indicated time points, basophils were collected in
FACS tubes and stained on ice in the dark for 30min:
hamster anti-FcεRI (clone MAR-1) and/or IL-3Rα/CD123
(clone 5B11), anti-CD45.2 (clone 104), or IgG2aκ isotype
(clone RTK2758) (BioLegend) were diluted in antibody
blocking buffer containing of 3% normal rat serum
(Invitrogen/ Thermo Fisher Scientiﬁc, Waltham, MA, US)
and 20% 2.4G2 hybridoma conditioned medium as source
of anti-CD16/CD32 FcRII/III blocking antibodies in
FACS buffer. Cells were washed once prior to ﬂow cyto-
metric analysis using FACS Verse or FACS Lyric. Gate
was set on viable single cells to analyze the variation of
the geometric mean upon the indicated stimuli. All
time points were set into relation of the expression level at
time point zero, corresponding to 100%. Data were ana-
lyzed using FlowJo version 10.1.
SDS-PAGE gel electrophoresis and quantitative
immunoblotting
After washing with PBS, 3 × 106 cells were directly lysed
in pre-heated H8 buffer (20mM Tris/HCl pH 7.5, 2 mM
EGTA, 2 mM EDTA, 1% SDS, supplemented with 50mM
DTT) and boiled and homogenized at 95 °C in the pre-
sence of 4× Lämmli buffer. Proteins were separated on
12.5% or 15% denaturing SDS-PAGE gels and transferred
to polyvinilydene diﬂuoride (PVDF) membrane (Immo-
bilon-FL, 0.45 μM, Merck Millipore, Zug, CH). After
blocking, the membranes were probed overnight with the
following primary antibodies: mouse anti-BCL-2 (clone
10C4, BioLegend); rat anti-BIM (clone 3C5) and rat anti-
MCL-1 (clone 14C11), kind gifts from D. Huang (Park-
ville, Australia); mouse anti-GSK-3α/β (clone 0011-A/
1H8) form Santa Cruz Biotechnology (Dellas, TX, US);
rabbit anti-phospho-AKT (Ser473) (clone D9E) and
mouse anti-AKT (clone 40D4) from Cell Signaling
Technology (Danvers, MA, US); mouse anti-tubulin
(clone B-5-1-2) from Sigma; mouse anti-GAPDH from
Merck Millipore (Zug, CH); mouse anti-actin from BD
Biosciences (San Jose, CA, US). For all immunoblots with
total lysates, near-infrared ﬂuorophore-conjugated sec-
ondary antibodies (LI-COR Biosciences, Bad Homburg,
DE) were used. All immunoblots were analyzed and
quantiﬁed with the Odyssey® Fc Dual-Mode Imaging
System using the ImageStudio software 3.1.4 (LI-COR).
RT2 proﬁler PCR array
5 × 106 basophils were incubated for 3 h in presence or
absence of 20 ng/ml IL-4, collected, washed twice in PBS,
and snap-frozen until further procession. Messenger RNA
was isolated using the SV Total RNA Isolation System from
Promega (Fitchburg, WI, US). RNA was reverse transcribed
using oligo d(T) primers and M-MLV reverse transcriptase
(Promega) according to the manufacturer’s instructions.
RT2 Proﬁler PCR array of mouse genes related with apop-
tosis (PAMM-012Z) was purchased from QIAGEN (Venlo,
NL). Using 5xHOT FIREPol EvaGreen qPCR master Mix
Plus (Solis BioDyne, Tartu, Estonia), array was run in CFX
Connect cycler with the following program: 15min at 95 °C,
40 cycles with 15 s at 95 °C, 1min at 60 °C followed by 1min
at 72 °C. Data analysis was performed using suppliers SA
Biosciences PCR array data analysis software (http://www.
sabiosciences.com/rt_pcr_product/HTML/PAMM-012Z.
html) and displayed in Prism 6 generated graph.
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AKT/PKB phospho antibody array
Lysates from untreated and IL-4 exposed basophils were
subjected to the AKT phospho-array (PARB216) from Full
Moon BioSystems, Inc. (Sunnyvale, CA, US) according to
the manufacturer’s protocol. Final analysis including slide
scanning and data evaluation was performed by Full Moon
BioSystems. The mean signal intensity of each spot on the
array was extracted, determining the average signal
intensity of all six replicated spots. The resulting average
signal was than normalized to the average signal back-
ground of each slide before the phospho side-speciﬁc
antibody signal was compared to the site-speciﬁc antibody.
Subsequently, the data obtained were compared between
IL-4 and untreated basophils and displayed using Prism
6 software (GraphPad, La Jolla, CA, USA). Complete data
is shown in Supplementary Table S1, showing increase in
protein phosphorylation in red, decrease in green.
Statistical analysis
Dose response analysis of IL-4 and its effect on forward
scatter (FSC)/side scatter (SSC) was analyzed by two-way
analysis of variance followed by post hoc multiple com-
parison correction with the method of either Dunnett for
the dose response or Turkey for FSC/SSC measurements.
Statistical analysis of quantitative western blot data and
viability kinetics were performed using multiple t test
determining signiﬁcance through Holm-Sidak correction,
with α= 0.05. All values are represented as means ± SD.
All statistical analysis was performed using Prism 6 soft-
ware (GraphPad, La Jolla, CA, USA).
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